Tobam Lowers Holdings in DaVita Inc. (NYSE:DVA)

Tobam lowered its stake in shares of DaVita Inc. (NYSE:DVA) by 65.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 15,129 shares of the company’s stock after selling 28,939 shares during the period. Tobam’s holdings in DaVita were worth $2,263,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. FMR LLC boosted its holdings in DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares in the last quarter. Glenmede Trust Co. NA raised its position in shares of DaVita by 731.6% in the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after acquiring an additional 108,446 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after acquiring an additional 92,014 shares in the last quarter. KBC Group NV increased its stake in shares of DaVita by 27.3% in the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after purchasing an additional 67,250 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new position in DaVita in the 3rd quarter worth about $10,346,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Down 2.8 %

DVA stock opened at $171.96 on Friday. The business’s 50-day moving average is $160.45 and its 200 day moving average is $156.11. DaVita Inc. has a 12-month low of $108.76 and a 12-month high of $179.60. The stock has a market cap of $14.10 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 0.86 and a beta of 0.93. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

Wall Street Analyst Weigh In

Separately, Barclays boosted their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.